Literature DB >> 14651589

In vitro selection of Plasmodium falciparum 3D7 for expression of variant surface antigens associated with severe malaria in African children.

Trine Staalsoe1, Morten A Nielsen, Lasse S Vestergaard, Anja T R Jensen, Thor G Theander, Lars Hviid.   

Abstract

P. falciparum-infected red blood cells (IRBC) can adhere to endothelial host receptors through parasite-encoded, clonally variant surface antigens (VSA). The VSA-mediated IRBC adhesion and the acquired VSA-specific antibody response have both been linked to IRBC organ tropism and disease severity. Parasites isolated from young children with severe malaria (SM) tend to express a limited and conserved set of VSA (VSASM) that are both stronger and more commonly recognized by IgG in the plasma of malaria-exposed individuals than VSA (VSAUM) expressed by parasites causing uncomplicated malaria (UM) in older semi-immune children. Establishment of the genetic mechanism underlying changes in VSA expression in response to in vitro selective pressure is now possible because of the availability of the entire genomic sequence of the P. falciparum clone 3D7. As a first step towards direct molecular identification of VSASM-encoding genes in 3D7, we report here a method of enforcing expression of VSASM-like antigens in this parasite clone by a novel selection method using plasma from semi-immune children with low VSAUM-specific, but high VSASM-specific, IgG reactivity. In addition to the resulting increase in VSA-specific IgG recognition, VSASM-expressing 3D7(3D7-Dodowa1) showed reduced adhesion to CD36. Finally, levels of IgG specific for the VSA expressed by 3D7-Dodowa1 were uniformly higher than those of IgG with specificity for VSA expressed by the unselected 3D7 in plasma samples from geographically and epidemiologically diverse areas of endemic parasite transmission. The described selection method appears a useful tool in the identification of genes encoding VSA involved in severe and life-threatening P. falciparum malaria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651589     DOI: 10.1111/j.1365-3024.2003.00652.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  34 in total

1.  Differential expression of var gene groups is associated with morbidity caused by Plasmodium falciparum infection in Tanzanian children.

Authors:  Matthias Rottmann; Thomas Lavstsen; Joseph Paschal Mugasa; Mirjam Kaestli; Anja T R Jensen; Dania Müller; Thor Theander; Hans-Peter Beck
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Programmed transcription of the var gene family, but not of stevor, in Plasmodium falciparum gametocytes.

Authors:  Sarah Sharp; Thomas Lavstsen; Quinton L Fivelman; Maha Saeed; Louisa McRobert; Thomas J Templeton; Anja T R Jensen; David A Baker; Thor G Theander; Colin J Sutherland
Journal:  Eukaryot Cell       Date:  2006-08

3.  Limited cross-reactivity among domains of the Plasmodium falciparum clone 3D7 erythrocyte membrane protein 1 family.

Authors:  Louise Joergensen; Louise Turner; Pamela Magistrado; Madeleine A Dahlbäck; Lasse S Vestergaard; John P Lusingu; Martha Lemnge; Ali Salanti; Thor G Theander; Anja T R Jensen
Journal:  Infect Immun       Date:  2006-10-02       Impact factor: 3.441

4.  Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA.

Authors:  Lea Barfod; Nadia L Bernasconi; Madeleine Dahlbäck; David Jarrossay; Pernille Haste Andersen; Ali Salanti; Michael F Ofori; Louise Turner; Mafalda Resende; Morten A Nielsen; Thor G Theander; Federica Sallusto; Antonio Lanzavecchia; Lars Hviid
Journal:  Mol Microbiol       Date:  2006-12-14       Impact factor: 3.501

5.  The kinetics of antibody binding to Plasmodium falciparum VAR2CSA PfEMP1 antigen and modelling of PfEMP1 antigen packing on the membrane knobs.

Authors:  Lars M Joergensen; Ali Salanti; Tina Dobrilovic; Lea Barfod; Tue Hassenkam; Thor G Theander; Lars Hviid; David E Arnot
Journal:  Malar J       Date:  2010-04-19       Impact factor: 2.979

6.  Insect cells are superior to Escherichia coli in producing malaria proteins inducing IgG targeting PfEMP1 on infected erythrocytes.

Authors:  Michala E Victor; Anja Bengtsson; Gorm Andersen; Dominique Bengtsson; John P Lusingu; Lasse S Vestergaard; David E Arnot; Thor G Theander; Louise Joergensen; Anja T R Jensen
Journal:  Malar J       Date:  2010-11-15       Impact factor: 2.979

7.  Immunoglobulin G antibody reactivity to a group A Plasmodium falciparum erythrocyte membrane protein 1 and protection from P. falciparum malaria.

Authors:  Pamela A Magistrado; John Lusingu; Lasse S Vestergaard; Martha Lemnge; Thomas Lavstsen; Louise Turner; Lars Hviid; Anja T R Jensen; Thor G Theander
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

8.  Geographical and temporal conservation of antibody recognition of Plasmodium falciparum variant surface antigens.

Authors:  Morten A Nielsen; Lasse S Vestergaard; John Lusingu; Jørgen A L Kurtzhals; Haider A Giha; Berit Grevstad; Bamenla Q Goka; Martha M Lemnge; James B Jensen; Bartholomew D Akanmori; Thor G Theander; Trine Staalsoe; Lars Hviid
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

9.  Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania.

Authors:  Lasse S Vestergaard; John P Lusingu; Morten A Nielsen; Bruno P Mmbando; Daniel Dodoo; Bartholomew D Akanmori; Michael Alifrangis; Ib C Bygbjerg; Martha M Lemnge; Trine Staalsoe; Lars Hviid; Thor G Theander
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

10.  Evidence for in vitro and in vivo expression of the conserved VAR3 (type 3) plasmodium falciparum erythrocyte membrane protein 1.

Authors:  Christian W Wang; Thomas Lavstsen; Dominique C Bengtsson; Pamela A Magistrado; Sanne S Berger; Andrea M Marquard; Michael Alifrangis; John P Lusingu; Thor G Theander; Louise Turner
Journal:  Malar J       Date:  2012-04-25       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.